NEW YORK (GenomeWeb News) – Promethera Biosciences today announced a collaboration with EMD Millipore to develop "an improved ready-to-use microfluidic perfusion liver assay."

Promethera added that it and EMD Millipore, a division of Germany's Merck KGaA, are receiving €900,000 ($1.2 million) from the Belgian Walloon Region Biocluster and the Massachusetts Life Sciences Center to support development of the assay, which is being designed so that "more robust studies in pre-clinical toxicity and drug metabolism" can be achieved.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.